CRSP Stock Forecast: CRISPR Therapeutics AG Price Predictions for 2026-2027
The 23 Wall Street analysts covering CRISPR Therapeutics AG hold a median 12-month price target of $80 — +104.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 33 of 100 as at 21 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
One number for the whole business
Consensus tells you what everyone already believes. The model scores CRISPR Therapeutics AG on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (67): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (14): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
CRSP stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CRSP, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +104.3% from it.
Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 Nov 2026 | Citigroup | Maintains | Buy | $88 → $90 |
| 4 Nov 2026 | Wells Fargo | Maintains | Equal-Weight | $75 → $70 |
| 3 Nov 2026 | Needham | Reiterates | Buy | $82 |
| 15 Oct 2026 | UBS | Initiates | Neutral | $52 |
| 31 Aug 2026 | Citizens | Reiterates | Market Outperform | $80 |
| 31 Aug 2026 | Needham | Reiterates | Buy | $82 |
| 25 Aug 2026 | Citizens | Reiterates | Market Outperform | $80 |
| 4 Aug 2026 | Citigroup | Maintains | Buy | $82 → $88 |
| 8 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $80 |
| 6 July 2026 | Citizens | Reiterates | Market Outperform | $80 |
| 13 May 2026 | Bernstein | Maintains | Market Perform | — |
| 6 May 2026 | Citigroup | Maintains | Buy | — |
| 17 Mar 2026 | Piper Sandler | Reiterates | Overweight | — |
| 17 Feb 2026 | Chardan Capital | Maintains | Buy | — |
| 13 Feb 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 13 Feb 2026 | Needham | Maintains | Buy | — |
| 13 Feb 2026 | TD Cowen | Maintains | Hold | — |
| 30 Jan 2026 | Citizens | Maintains | Market Outperform | — |
| 23 Dec 2025 | Citizens | Reiterates | Market Outperform | — |
| 23 Dec 2025 | Needham | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CRSP.
This page is one stock. Monday covers all of them.
CRSP appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
CRSP vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, CRISPR Therapeutics AG returned −20.6% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
CRSP analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 153.3×
- Price / book
- 2.3×
- EV / EBITDA
- —
Cheaper than 3% of US stocks
Cheaper than 38% of US stocks
- Revenue growth (YoY)
- 1325.1%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
Higher than 99% of US stocks
- Return on equity
- −25.6%
- Return on assets
- −13.5%
- Dividend yield
- —
Higher than 30% of US stocks
Higher than 24% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
CRISPR Therapeutics AG has a market value of $3.8B and an enterprise value of $2.3B.
Revenue in the twelve months to 30 June 2026: $11.0M.
Net income over the same four quarters: −$451.1M, a −4101.3% net margin.
Diluted earnings per share, trailing twelve months: −$4.76.
Free cash flow in the twelve months to 30 June 2026: −$373.8M.
CRISPR Therapeutics AG employs 393 people — $28K of revenue per employee.
Data provided by Twelve Data
CRSP and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at CRSP’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own CRISPR Therapeutics AG — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about CRSP
What is the CRSP stock price forecast for 2026-2027?
The 23 Wall Street analysts covering CRISPR Therapeutics AG have a median 12-month price target of $80, with estimates ranging from $44 to $291. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is CRSP stock a buy right now?
Of the 23 analysts covering CRISPR Therapeutics AG, 13 rate it a Buy, 10 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CRISPR Therapeutics AG 33 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank CRSP?
As at 21 Nov 2026, CRISPR Therapeutics AG ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (67 of 100).
Will CRSP stock go up?
No one can know that. What the data says: the median 12-month target from 23 analysts implies +104.3% from the last close, and Ticker Nerd's factor model ranks CRISPR Therapeutics AG 33 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the CRSP stock forecast for 2030?
No analyst covering CRISPR Therapeutics AG publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRSP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $44 to $291 over the next 12 months.
How has CRSP stock performed over the past year?
CRISPR Therapeutics AG returned -20.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does CRISPR Therapeutics AG do?
CRISPR Therapeutics AG is a biotechnology company developing gene-based medicines for serious diseases through its CRISPR/Cas9 gene-editing platform. Its work includes ex vivo therapies, in which a patient’s cells are edited outside the body before reinfusion, and in vivo approaches designed to modify genetic targets directly within the body.
About CRISPR Therapeutics AG.
CRISPR Therapeutics AG is a biotechnology company developing gene-based medicines for serious diseases through its CRISPR/Cas9 gene-editing platform. Its work includes ex vivo therapies, in which a patient’s cells are edited outside the body before reinfusion, and in vivo approaches designed to modify genetic targets directly within the body. The company’s current portfolio spans blood disorders, oncology, autoimmune diseases, cardiovascular conditions, and type 1 diabetes. Its leading therapy, CASGEVY, is a gene-edited cell therapy for transfusion-dependent beta-thalassemia and severe sickle cell disease that edits blood-forming stem cells to support production of fetal hemoglobin. CRISPR Therapeutics AG also develops allogeneic CAR T-cell programs intended to address cancer and autoimmune indications, alongside gene-editing candidates targeting cardiovascular risk factors and stem-cell-derived therapies for diabetes. Headquartered in Zug, Switzerland, the company operates at the intersection of biotechnology, cell therapy, and precision medicine, contributing to the development of treatments that address disease at the genetic or cellular level.
CEO Dr. Samarth Kulkarni Ph.D. · 393 employees · Switzerland · https://www.crisprtx.com